Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 97562 | 4.37 |
09:34 ET | 14084 | 4.4 |
09:36 ET | 19514 | 4.385 |
09:38 ET | 28688 | 4.38 |
09:39 ET | 14691 | 4.37 |
09:41 ET | 57373 | 4.375 |
09:43 ET | 47508 | 4.345 |
09:45 ET | 27833 | 4.39 |
09:48 ET | 11450 | 4.35 |
09:50 ET | 5117 | 4.35 |
09:52 ET | 44929 | 4.365 |
09:54 ET | 20607 | 4.38 |
09:56 ET | 28641 | 4.34 |
09:57 ET | 6400 | 4.325 |
09:59 ET | 18151 | 4.33 |
10:01 ET | 10006 | 4.34 |
10:03 ET | 11588 | 4.34 |
10:06 ET | 14670 | 4.355 |
10:08 ET | 7533 | 4.36 |
10:10 ET | 10483 | 4.345 |
10:12 ET | 14225 | 4.35 |
10:14 ET | 6286 | 4.35 |
10:15 ET | 25984 | 4.345 |
10:17 ET | 3578 | 4.35 |
10:19 ET | 8179 | 4.35 |
10:21 ET | 24242 | 4.34 |
10:24 ET | 5268 | 4.35 |
10:26 ET | 40234 | 4.37 |
10:28 ET | 8765 | 4.36 |
10:30 ET | 3500 | 4.36 |
10:32 ET | 11002 | 4.36 |
10:33 ET | 18491 | 4.37 |
10:35 ET | 21612 | 4.37 |
10:37 ET | 8986 | 4.37 |
10:39 ET | 7170 | 4.365 |
10:42 ET | 8375 | 4.37 |
10:44 ET | 6987 | 4.3775 |
10:46 ET | 4472 | 4.38 |
10:48 ET | 17759 | 4.375 |
10:50 ET | 22522 | 4.385 |
10:51 ET | 42650 | 4.365 |
10:53 ET | 5660 | 4.36 |
10:55 ET | 37669 | 4.36 |
10:57 ET | 3212 | 4.36 |
11:00 ET | 2844 | 4.36 |
11:02 ET | 13509 | 4.345 |
11:04 ET | 8593 | 4.36 |
11:06 ET | 21109 | 4.37 |
11:08 ET | 7123 | 4.365 |
11:09 ET | 5096 | 4.365 |
11:11 ET | 3620 | 4.37 |
11:13 ET | 19378 | 4.385 |
11:15 ET | 8866 | 4.38 |
11:18 ET | 5623 | 4.375 |
11:20 ET | 8902 | 4.375 |
11:22 ET | 22203 | 4.365 |
11:24 ET | 16894 | 4.365 |
11:26 ET | 17831 | 4.37 |
11:27 ET | 4122 | 4.37 |
11:29 ET | 4387 | 4.37 |
11:31 ET | 8756 | 4.375 |
11:33 ET | 15229 | 4.385 |
11:36 ET | 28467 | 4.4075 |
11:38 ET | 8811 | 4.405 |
11:40 ET | 61893 | 4.4 |
11:42 ET | 68659 | 4.395 |
11:44 ET | 67243 | 4.405 |
11:45 ET | 45644 | 4.405 |
11:47 ET | 3635 | 4.42 |
11:49 ET | 64699 | 4.43 |
11:51 ET | 29430 | 4.43 |
11:54 ET | 4820 | 4.43 |
11:56 ET | 23267 | 4.43 |
11:58 ET | 18058 | 4.42 |
12:00 ET | 3694 | 4.42 |
12:02 ET | 20541 | 4.42 |
12:03 ET | 17059 | 4.415 |
12:05 ET | 82421 | 4.435 |
12:07 ET | 45436 | 4.46 |
12:09 ET | 21455 | 4.455 |
12:12 ET | 53375 | 4.4601 |
12:14 ET | 16271 | 4.47 |
12:16 ET | 32848 | 4.48 |
12:18 ET | 5539 | 4.48 |
12:20 ET | 16139 | 4.48 |
12:21 ET | 10606 | 4.475 |
12:23 ET | 108383 | 4.475 |
12:25 ET | 9529 | 4.48 |
12:27 ET | 5821 | 4.475 |
12:30 ET | 77073 | 4.49 |
12:32 ET | 144000 | 4.475 |
12:34 ET | 28459 | 4.48 |
12:36 ET | 10444 | 4.48 |
12:38 ET | 5040 | 4.48 |
12:39 ET | 5968 | 4.48 |
12:41 ET | 4759 | 4.475 |
12:43 ET | 12111 | 4.48 |
12:45 ET | 46639 | 4.49 |
12:48 ET | 6741 | 4.49 |
12:50 ET | 8099 | 4.49 |
12:52 ET | 6106 | 4.485 |
12:54 ET | 56254 | 4.5 |
12:56 ET | 3562 | 4.5 |
12:57 ET | 50354 | 4.49 |
12:59 ET | 3520 | 4.485 |
01:01 ET | 4569 | 4.485 |
01:03 ET | 42479 | 4.4893 |
01:06 ET | 56595 | 4.495 |
01:08 ET | 27371 | 4.495 |
01:10 ET | 11231 | 4.495 |
01:12 ET | 9069 | 4.495 |
01:14 ET | 58641 | 4.5 |
01:15 ET | 13915 | 4.5 |
01:17 ET | 4837 | 4.5 |
01:19 ET | 8831 | 4.5 |
01:21 ET | 17848 | 4.51 |
01:24 ET | 3450 | 4.51 |
01:26 ET | 2300 | 4.51 |
01:28 ET | 59984 | 4.5 |
01:30 ET | 10830 | 4.5 |
01:32 ET | 5976 | 4.495 |
01:33 ET | 10703 | 4.5 |
01:35 ET | 3700 | 4.5 |
01:37 ET | 35790 | 4.5 |
01:39 ET | 11568 | 4.5 |
01:42 ET | 15700 | 4.5 |
01:44 ET | 3100 | 4.5 |
01:46 ET | 5021 | 4.5 |
01:48 ET | 6684 | 4.5 |
01:50 ET | 5769 | 4.4947 |
01:51 ET | 52110 | 4.505 |
01:53 ET | 26054 | 4.495 |
01:55 ET | 1400 | 4.5 |
01:57 ET | 3318 | 4.495 |
02:00 ET | 4656 | 4.5 |
02:02 ET | 3937 | 4.495 |
02:04 ET | 8484 | 4.5 |
02:06 ET | 7798 | 4.495 |
02:08 ET | 4528 | 4.495 |
02:09 ET | 3046 | 4.5 |
02:11 ET | 12450 | 4.5 |
02:13 ET | 4500 | 4.495 |
02:15 ET | 3613 | 4.5 |
02:18 ET | 5905 | 4.495 |
02:20 ET | 8279 | 4.495 |
02:22 ET | 23694 | 4.495 |
02:24 ET | 9881 | 4.495 |
02:26 ET | 50654 | 4.505 |
02:27 ET | 27002 | 4.495 |
02:29 ET | 3314 | 4.4932 |
02:31 ET | 48377 | 4.5 |
02:33 ET | 12688 | 4.495 |
02:36 ET | 3400 | 4.5 |
02:38 ET | 8632 | 4.5 |
02:40 ET | 2507 | 4.495 |
02:42 ET | 8647 | 4.495 |
02:44 ET | 4100 | 4.495 |
02:45 ET | 9400 | 4.495 |
02:47 ET | 4948 | 4.495 |
02:49 ET | 8799 | 4.495 |
02:51 ET | 15654 | 4.5 |
02:54 ET | 7036 | 4.495 |
02:56 ET | 8610 | 4.495 |
02:58 ET | 18144 | 4.495 |
03:00 ET | 10246 | 4.495 |
03:02 ET | 31357 | 4.495 |
03:03 ET | 36281 | 4.5 |
03:05 ET | 30183 | 4.495 |
03:07 ET | 23142 | 4.505 |
03:09 ET | 33932 | 4.51 |
03:12 ET | 20267 | 4.515 |
03:14 ET | 4018 | 4.515 |
03:16 ET | 40552 | 4.51 |
03:18 ET | 19669 | 4.505 |
03:20 ET | 4669 | 4.51 |
03:21 ET | 3660 | 4.505 |
03:23 ET | 21937 | 4.51 |
03:25 ET | 25453 | 4.505 |
03:27 ET | 7709 | 4.505 |
03:30 ET | 4332 | 4.505 |
03:32 ET | 39428 | 4.51 |
03:34 ET | 12435 | 4.51 |
03:36 ET | 10340 | 4.51 |
03:38 ET | 17591 | 4.515 |
03:39 ET | 70391 | 4.53 |
03:41 ET | 35579 | 4.53 |
03:43 ET | 60092 | 4.535 |
03:45 ET | 5397 | 4.5349 |
03:48 ET | 31877 | 4.525 |
03:50 ET | 15710 | 4.525 |
03:52 ET | 114222 | 4.525 |
03:54 ET | 17296 | 4.525 |
03:56 ET | 197725 | 4.54 |
03:57 ET | 114622 | 4.525 |
03:59 ET | 246712 | 4.53 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.7B | -13.1x | --- |
MoonLake Immunotherapeutics | 2.7B | -56.0x | --- |
Xenon Pharmaceuticals Inc | 2.8B | -13.6x | --- |
SpringWorks Therapeutics Inc | 2.7B | -7.1x | --- |
IDEAYA Biosciences Inc | 2.6B | -17.1x | --- |
Celldex Therapeutics Inc | 2.3B | -12.5x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -13.1x |
Price/Sales (TTM) | 5,167.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.